Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board

Outrun Therapeutics Scotland United Kingdom

Lead programme based on a first?in?class small?molecule E6AP ubiquitin ligase inhibition strategy for the treatment of HPV?positive head and neck cancer Programme has demonstrated strong in vitro and in vivo proof of mechanism, and is expected to enter the clinic in 2027Progress is complemented with formation of world-class SAB, including leading experts in E3 ligase biology and head and neck cancerView original content:https://www.prnewswire.co.uk/news-releases/outrun-therapeutics-unveils-lead-programme-targeting-hpv-positive-head-and-neck-cancer-and-appoints-renowned-e3-ligase-experts-to-scientific-advisory-board-sab-302715003.html